HELLP Syndrome, Preeclampsia, Pregnancy, Preterm Premature Rupture of Fetal Membranes
Conditions
Keywords
Pancreatic stone protein (PSP), premature rupture of membranes (PPROM), amniotic infection syndrome (AIS), hemolysis, elevated liver enzymes, and low platelets (HELLP), preeclampsia, pregnancy
Brief summary
This prospective, single centred cohort study evaluates the physiological course of the potentially novel biomarker PSP in pregnant women as well as its predictive role in the development of inflammatory complications during pregnancy.
Detailed description
Pregnant women feature a complex immunological condition caused by pregnancy itself and hence women present with an increased susceptibility to some infectious and non-infectious inflammatory diseases. Specifically regulated mechanisms have been described occurring in normal whereas lacking in pathological pregnancies in both the native and adaptive immune system in animal models and humans. However, clinically relevant biomarker associated with preterm premature rupture of membranes (PPROM), amniotic infection syndrome (AIS) as well as pregnancy associated complications such as preeclampsia and hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome have their limitations. Pancreatic stone protein (PSP), originally obtained from human pancreatic stones from patients operated for chronic calcifying pancreatitis, has been studied in several gastrointestinal pathologies. The aim of this study is to evaluate the physiological course of the potentially novel biomarker PSP in pregnant women as well as to assess its predictive role in the development of inflammatory complications during pregnancy.
Interventions
PROCEDUREBlood collection
Diagnostic blood collection
Sponsors
University of Zurich
Nicole Ochsenbein
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 18 years * Healthy women with single pregnancy * Women with PPROM, AIS, preeclampsia, or HELLP syndrome * Patients able to provide informed consent
Exclusion criteria
* Viral (hepatitis B virus, hepatitis C virus, human immunodeficiency virus) or confirmed bacterial infections
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Physiological course of PSP in healthy pregnant women | 34 weeks | Measurement of serum PSP through ELISA (Enzyme Linked Immunosorbent Assay) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Predictive role of PSP in the development of complications during pregnancy | 34 weeks | Measurement of serum PSP through ELISA (Enzyme Linked Immunosorbent Assay) |
Countries
Switzerland
Contacts
Primary ContactNicole Ochsenbein, Prof. Dr.
Backup ContactNora Gadient, Dr. med.
Outcome results
None listed